Thomas Trimarchi Sells 13,600 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BridgeBio Pharma Stock Down 4.3%

Shares of BBIO stock opened at $70.72 on Friday. The stock’s fifty day simple moving average is $75.66 and its 200 day simple moving average is $63.84. BridgeBio Pharma, Inc. has a twelve month low of $28.33 and a twelve month high of $84.94. The firm has a market capitalization of $13.63 billion, a P/E ratio of -16.92 and a beta of 1.13.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

Institutional Trading of BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in BBIO. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma during the first quarter valued at $35,000. Vanguard Personalized Indexing Management LLC boosted its position in BridgeBio Pharma by 5.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 16,178 shares of the company’s stock worth $699,000 after purchasing an additional 772 shares during the period. CWM LLC raised its position in shares of BridgeBio Pharma by 29.8% in the second quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after purchasing an additional 1,569 shares during the period. Allianz Asset Management GmbH grew its stake in BridgeBio Pharma by 57.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 12,300 shares of the company’s stock valued at $531,000 after buying an additional 4,500 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in BridgeBio Pharma during the 2nd quarter valued at $229,000. Institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on BBIO shares. Sanford C. Bernstein initiated coverage on BridgeBio Pharma in a research note on Thursday, December 11th. They set an “outperform” rating and a $94.00 target price for the company. Truist Financial lifted their price objective on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Piper Sandler increased their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Oppenheimer lifted their price target on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Finally, Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.05.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.